DISEASE INDICATIONS: Leukemia
MANUFACTURER: Novartis Europharm Limited
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Rydapt is a groundbreaking medication, primarily used in combination with standard chemotherapy for newly diagnosed AML patients who have a specific genetic mutation known as FLT3 mutation.
